Welcome to the Abel Lab
Care Delivery Research for Patients with Blood Cancers
The Abel Lab at Dana-Farber Cancer Institute applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve care.
|
We are interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through our work and collaboration with researchers in oncology, hematology, geriatrics, ethics, and energy balance, we aim to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life. |
|
|
|
Dr. Abel discusses the care delivery and bioethics impact of telemedicine implementation at Dana-Farber with Dr. Wagner, the Medical Director of Adult Ambulatory Oncology. Explore this website to learn about the Abel Lab’s current research and former projects. |
Lab News — Spring 2025 |
- Results of the Abel Lab’s PCORI-funded randomized clinical trial of shared care after allogeneic stem cell transplantation were published in JAMA Oncology.
- Dr. Blackstone’s commentary, “Timely reporting of patient-reported outcomes in cancer clinical trials: An ethical imperative” was published in the Journal of Clinical Oncology.
- Dr. Odejide’s analysis “Anxiety and depression among patients newly diagnosed with lymphoma and myeloma” was published in Blood Advances.
- Dr. Kelkar’s analysis “Pre-transplant measures of geriatric assessment domains and outcomes of allogeneic hematopoietic cell transplantation in adults aged 75 and older” was selected for poster presentation at the 2025 annual meeting of the American Society of Clinical Oncology in June.
|
|
|